BDBM451801 US10710980, Example 33::US10947218, Example 33

SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1CCOCC1

InChI Key InChIKey=JHBVJUXBKKKJGW-UHFFFAOYSA-N

Data  14 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 14 hits for monomerid = 451801   

TargetActivin receptor type-1 [172-499](Human)
Novartis

US Patent
LigandPNGBDBM451801(US10710980, Example 33 | US10947218, Example 33)
Affinity DataIC50: 10nMAssay Description:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 6 ul. Dose-response curves were generated by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
Go to US Patent

LigandPNGBDBM451801(US10710980, Example 33 | US10947218, Example 33)
Affinity DataIC50: 2.40E+3nMAssay Description:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 6 ul. Dose-response curves were generated by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
Go to US Patent

TargetActivin receptor type-1 [172-499](Human)
Novartis

US Patent
LigandPNGBDBM451801(US10710980, Example 33 | US10947218, Example 33)
Affinity DataIC50: 20nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples ( 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
Go to US Patent

TargetActivin receptor type-1 [172-499,R206H](Human)
Novartis

US Patent
LigandPNGBDBM451801(US10710980, Example 33 | US10947218, Example 33)
Affinity DataIC50: 14nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples ( 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
Go to US Patent

LigandPNGBDBM451801(US10710980, Example 33 | US10947218, Example 33)
Affinity DataIC50: 220nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples ( 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1 [162-503](Human)
Novartis

US Patent
LigandPNGBDBM451801(US10710980, Example 33 | US10947218, Example 33)
Affinity DataIC50: 1.80E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples ( 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
Go to US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
Novartis

US Patent
LigandPNGBDBM451801(US10710980, Example 33 | US10947218, Example 33)
Affinity DataIC50: 2.00E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples ( 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
Go to US Patent

TargetActivin receptor type-1 [172-499](Human)
Novartis

US Patent
LigandPNGBDBM451801(US10710980, Example 33 | US10947218, Example 33)
Affinity DataIC50: 10nMAssay Description:A kinase selectivity panel which measures autophosphorylation using the ADP-Glo Kinase Assay (Promega, V9101) was set-up for wild-type ALK2 (aa172-49...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
Go to US Patent

LigandPNGBDBM451801(US10710980, Example 33 | US10947218, Example 33)
Affinity DataIC50: 2.40E+3nMAssay Description:A kinase selectivity panel which measures autophosphorylation using the ADP-Glo Kinase Assay (Promega, V9101) was set-up for wild-type ALK2 (aa172-49...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
Go to US Patent

TargetActivin receptor type-1 [172-499](Human)
Novartis

US Patent
LigandPNGBDBM451801(US10710980, Example 33 | US10947218, Example 33)
Affinity DataIC50: 20nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
Go to US Patent

TargetActivin receptor type-1 [172-499,R206H](Human)
Novartis

US Patent
LigandPNGBDBM451801(US10710980, Example 33 | US10947218, Example 33)
Affinity DataIC50: 14nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
Go to US Patent

LigandPNGBDBM451801(US10710980, Example 33 | US10947218, Example 33)
Affinity DataIC50: 220nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1 [162-503](Human)
Novartis

US Patent
LigandPNGBDBM451801(US10710980, Example 33 | US10947218, Example 33)
Affinity DataIC50: 1.80E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
Go to US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
Novartis

US Patent
LigandPNGBDBM451801(US10710980, Example 33 | US10947218, Example 33)
Affinity DataIC50: 2.00E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
Go to US Patent